PharmaShots | Incisive News in 3 Shots

Subscribe Now

Endeavor BioMedicines

Endeavor BioMedicines Reports the First Patient Dosing Under P-IIb (WHISTLE-PF) Study of Taladegib (ENV-101) to Treat Idiopathic Pulmonary Fibrosis

Endeavor BioMedicines Reports the First Patient Dosing Under P-IIb (WHISTLE-PF) Study of Taladegib (ENV-101) to Treat Idiopathic P...

November 21, 2024

Endeavor BioMedicines Reports Results from the P-IIa Study of ENV-101 for Treating Idiopathic Pulmonary Fibrosis

Endeavor BioMedicines Reports Results from the P-IIa Study of ENV-101 for Treating Idiopathic Pulmonary Fibrosis

May 20, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us